Peptide & Compound Guide
At a glance
| Compound | CJC-1295 |
|---|---|
| Type | Long-acting growth-hormone-releasing hormone analogue |
| U.S. regulatory context | Not FDA approved |
| Evidence level | Limited human research / investigational |
| Research area | Growth-hormone and IGF-1 physiology |
What is CJC-1295?
CJC-1295 is a synthetic analogue designed to extend growth-hormone-releasing hormone activity. Small human studies have investigated its effects on growth hormone and IGF-1 levels.
What does the research examine?
Changes in hormone levels are pharmacologic findings; they do not by themselves prove improvements in body composition, athletic performance, recovery or longevity.
What has not been established?
Mechanism, biomarker changes, animal findings and early clinical signals are not the same as proof that a compound safely improves meaningful health outcomes. Claims should be matched to the type, size and quality of evidence available.
Safety and regulatory context
Long-term safety and clinical benefit are not established for general anti-aging or performance use.
Related: CJC-1295 vs. Ipamorelin
Research sources
Use primary and authoritative sources when evaluating claims about this compound. Search results can change as new research is published.